Skip to content

US · KZIA · BIOTECHNOLOGY

Kazia Therapeutics Ltd ADR (KZIA) intrinsic value and stock valuation

$4.92as of 2026-11-21 · Mkt cap 22.49M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kazia Therapeutics Ltd ADR DCF and intrinsic value

InvestorsCraft values KZIA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from KZIA’s statements →

Kazia Therapeutics Ltd ADR Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Sydney, NSW 2000 kaziatherapeutics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$40K-47.4% 5y CAGRd
20112025
Net income
-$-20.7M
20112025
Free cash flow
-$-13.28M
20112025
Total equity
-$-8.3M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$40K$2.31M$0.00$10K$15.2M
Operating income-$-14.22M-$-28.46M-$-24.12M-$-25.4M-$-6.38M
Net income-$-20.7M-$-26.78M-$-20.47M-$-25.01M-$-8.42M
EPSd-$-18.82M-$-55.79M-$-55.32M-$-92.63M-$-35.08M
Operating cash flow-$-13.28M-$-9.58M-$-15.16M-$-22.76M-$-9.11M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-13.28M-$-9.58M-$-15.16M-$-22.76M-$-9.11M
Total assets$6.06M$21.6M$28.1M$35.9M$58.1M
Total debt$400K$630K$1.8M$1.84M$0.00
Net debt-$-3.95M-$-1.02M-$-3.44M-$-5.52M-$-27.59M
Total equity-$-8.3M-$-10.02M$12.1M$18.3M$37.9M
Cash and short-term investments$4.34M$1.66M$5.24M$7.36M$27.6M
Income statement
20252024202320222021
Revenue$40K$2.31M$0.00$10K$15.2M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$40K$2.31M$0.00$10K$15.2M
Research and development expenses$7.33M$17.4M$15.6M$20.2M$14.5M
Selling, general and administrative expenses$8.72M$13.6M$8.58M$5.24M$7.02M
Other expenses-$-1.79M-$-170K-$-20K$0.00-$0.00
Operating expenses$14.3M$30.8M$24.1M$25.4M$21.6M
Cost and expenses$14.3M$30.8M$24.1M$25.4M$21.6M
Interest income$70K$10K$20K$0.00$40K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$930K$1.87M$1.87M$1.87M$1.26M
Ebitda-$-13.28M-$-26.59M-$-22.28M-$-23.52M-$-5.11M
Operating income-$-14.22M-$-28.46M-$-24.12M-$-25.4M-$-6.38M
Total other income/expenses, net-$-8.23M$1.41M$3.41M$20K-$-2.53M
Income before tax-$-22.45M-$-27.05M-$-20.74M-$-25.38M-$-8.9M
Income tax expense-$-1.75M-$-270K-$-270K-$-370K-$-480K
Net income-$-20.7M-$-26.78M-$-20.47M-$-25.01M-$-8.42M
Weighted average shares outstanding$1.1M$480K$370K$270K$240K
Weighted average diluted shares outstanding$1.1M$480K$370K$270K$240K
Balance sheet
20252024202320222021
Cash and short-term investments$4.34M$1.66M$5.24M$7.36M$27.6M
Net receivables$90K$130K$100K$50K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$4.93M$6.14M$10.8M$9.45M$29.4M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$1.09M$15.4M$17.3M$19.1M$22M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.13M$15.4M$17.3M$26.4M$28.7M
Total assets$6.06M$21.6M$28.1M$35.9M$58.1M
Accounts payable$5.64M$4.55M$860K$1.52M$1.89M
Short-term debt$400K$630K$1.8M$1.84M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$14.1M$25.8M$7.57M$6.73M$8.33M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$310K$5.8M$8.47M$10.9M$11.9M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$14.4M$31.6M$16M$17.6M$20.2M
Common stock$123.1M$101.6M$97.5M$84.5M$80.3M
Retained earnings-$-134.83M-$-115.13M-$-89.08M-$-68.62M-$-44.2M
Accumulated other comprehensive income (loss)$3.1M$3.48M$3.68M$2.41M$1.76M
Total equity-$-8.3M-$-10.02M$12.1M$18.3M$37.9M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$400K$630K$1.8M$1.84M$0.00
Net debt-$-3.95M-$-1.02M-$-3.44M-$-5.52M-$-27.59M
Cash flow statement
20252024202320222021
Net income-$-20.7M-$-26.78M-$-20.46M-$-25.01M-$-8.42M
Depreciation and amortization$930K$1.87M$1.87M$1.87M$1.26M
Stock-based compensation$650K$530K$1.16M$1.68M$640K
Change in working capital-$-3.01M$10M$4.33M$860K-$-5.59M
Accounts receivable$3.8M$10K$3.45M-$-10K-$-5.03M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-13.28M-$-9.58M-$-15.16M-$-22.76M-$-9.11M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00-$-2.37M$0.00
Net cash used for investing activities$0.00$0.00$0.00-$-2.37M$0.00
Common stock issued$14.8M$5.58M$13M$3.73M$28.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$16M$5.99M$13M$3.73M$28.1M
Net change in cash$2.69M-$-3.58M-$-2.12M-$-20.23M$18.8M
Cash at end of period$4.34M$1.66M$5.24M$7.36M$27.6M
Operating cash flow-$-13.28M-$-9.58M-$-15.16M-$-22.76M-$-9.11M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-13.28M-$-9.58M-$-15.16M-$-22.76M-$-9.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kazia Therapeutics Ltd ADR

        Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

        CEO
        John Friend
        Employees
        6
        Beta
        2.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Kazia Therapeutics Ltd ADR (KZIA)?

        Kazia Therapeutics Ltd ADR (KZIA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KZIA undervalued?

        KZIA trades at a price of $4.92 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.